OARS funding Cancer

We fund projects at each stage of the drug development pipeline to ensure promising leads are advanced as quickly as possible. Our pre-clinical screening program breaks down barriers to entry, our academic grants focus on novel therapies, and our industry investments bring the most promising treatments to patients quickly.

The AACR and its Chemistry in Cancer Research Working Group established this award in 2007 to recognize the importance of chemistry to advancements in cancer research. The award will be given for outstanding, novel and significant chemistry research, which has led to important contributions to the fields of basic cancer research, translational cancer research, cancer diagnosis, the prevention of cancer or the treatment of patients with cancer. Such research may include, but is not limited to, drug discovery and design; structural biology; proteomics, metabolomics and biological mass spectrometry; chemical aspects of carcinogenesis; imaging agents and radiotherapeutics; and chemical biology.

Grants awarded by Ohio Cancer Research Associates are made to support research activities broadly related to cancer and leukemia. Certain types of projects are not recommended for support. Among these are purely clinical work of a non-research nature and requests for the sole purpose of equipping a laboratory.   All studies carried out as part of the proposed project must meet standards of informed consent for human subjects and/or proper care for animal subjects. Institutional approval of all research protocols involving human subjects or animal subjects must accompany the grant application.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The goal of this NHLBI R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral, and clinical research workforce in the mission areas of importance to NHLBI. To accomplish the stated goal, this funding opportunity announcement encourages the development of creative educational activities with a primary focus on Research Experiences.

The Experimental Program to Stimulate Competitive Research (EPSCoR) is a program designed to fulfill the National Science Foundation's (NSF) mandate to promote scientific progress nationwide. The EPSCoR program is directed at jurisdictions that have historically received lesser amounts of NSF Research and Development (R&D) funding. Thirty-one jurisdictions including twenty-eight states, the Commonwealth of Puerto Rico, the U. S. Virgin Islands, and Guam currently are eligible to participate. Through this program, NSF establishes partnerships with government, higher education, and industry that are designed to effect lasting improvements in a state's or region's research infrastructure, R&D capacity and hence, its national R&D competitiveness.Research Infrastructure Improvement Program: Track-2 (RII Track-2) awards provide funds in the range of $1.5 to 2.0 million per year for up to 3 years to consortia of EPSCoR jurisdictions. The awards promote opportunities for collaborations among EPSCoR jurisdictions in all areas of science, engineering, and education supported by the National Science Foundation (NSF). RII Track-2 proposals must describe a clear, comprehensive, and integrated vision to drive discovery, and train a skilled workforce capable of solving science and engineering challenges of regional, thematic, and national relevance. Proposals should also include a strong rationale for the establishment of the consortium and clearly demonstrate that the consortium is well-positioned to produce results that cannot be obtained by any single partner working independently. The Science, Technology, Engineering, and Mathematics (STEM) research and education activities should broaden participation by different types of institutions, individuals, and sectors in the project.

Purpose: This award is named in memory of Dr. Mary Nowotny, an active ONS member and past chair of the ONS Education Committee.  She was a cancer-education advocate throughout her career and a widely published author, writing many articles on the measurement and significance of hope in patients with cancer.  The Mary Nowotny Excellence in Cancer Nursing Education award recognizes and supports excellence in cancer nursing education.

This award is in memory of Linda Arenth, an active ONS and ONCC member who served as the Johns Hopkins Cancer Center's first director of nursing.  She started what is now a nationally known system to assign nursing services for different categories of cancer patients.  This award recognizes and supports excellence in both cancer nursing management and administration.

The purpose of the Kirschstein-NRSA postdoctoral fellowship is to enhance the research training of promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers.

The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers.

What do you get when you mix the view and excitement of Baltimore's Inner Harbor with about 700 grant administrators and researchers from around the world, then add more than 40 NIH and HHS experts in in one location who are eager to share their experiences and knowledge of the NIH grants process? You get the 2014 NIH Regional Seminar on Program Funding and Grants Administration, of course! Once again, "Charm City" will be the location for this once-a-year event June 25-27 at the Renaissance Baltimore Harborplace Hotel. Don't miss this exciting opportunity for investigators, administrators, grant writers and others who are new to the NIH grants process and/or those wanting to hear the latest NIH grants policy and process information first-hand. Learn how to successfully submit an application, navigate on-line resources, gain a better understanding of the peer review process, and hear about the expectations for managing your award.

Grants distributed from Alex's Lemonade Stand Foundation are designed to fill critical voids in current pediatric cancer research.

The Lung Cancer Research Foundation supports research on innovative strategies for better treatments, screening, and prevention of all cancers of the lung. The foundation's goal is to fund promising scientific and clinical research initiatives that lead to more positive outcomes and improved quality of life for all lung cancer patients. To that end, LCRF has issued a Request for Proposals designed to provide critical seed support for cutting-edge scientific research on all lung cancers. Through its Research Grant program, the foundation will support projects with a focus on basic science, translational research, clinical research, supportive care, and quality of care/outcomes.

We're looking for big thinkers to create innovations and solutions improving the daily lives of people facing cancer.

The Landon Foundation-AACR INNOVATOR Award for Research in Tumor Microenvironment was established to recognize the outstanding achievement of a junior faculty-level scientist working in the tumor microenvironment field, and support his or her research that, if successful, will have potential to advance knowledge on the tumor microenvironment. The goal of the grant program is to encourage junior faculty who are in the first five years of a faculty appointment (at the start of the grant term) to pursue novel tumor microenvironment research. Travel support is included to help foster interactions and collaborations among cancer scientists studying various aspects of cancer biology and to disseminate scientific knowledge about tumor microenvironment research within the field. Proposed projects may be basic, translational, clinical, or epidemiological in nature and must focus on the study of various aspects of the tumor microenvironment; including, but not limited to, the role of stroma and extracellular matrix in tumor development, angiogenesis, immunity and inflammation in the tumor microenvironment, as well as approaches to therapeutically target the tumor environment. The grant provides $100,000 over two years ($50,000 per year) for expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students, and/or research assistants, research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, other research expenses, and for attendance at an AACR annual meeting, any AACR tumor microenvironment-related conference, or other AACR meeting for the purpose of participating in scholarly exchange about the funded research.

To stimulate research that will generate new knowledge of the effects of the US healthcare system structure and the role of insurance on both access to and outcomes of cancer screening, early detection and treatment services. Studies investigating how one or more factors impacting access and outcomes interact - such as insurance status, costs, capacity, personal characteristics, provider characteristics, components of the healthcare delivery system and other known factors - are encouraged.

R&D Systems is offering ten $1,000 travel grants to attend the 105th Annual Meeting of the American Association for Cancer Research, held in San Diego, CA, April 5-9, 2014. Fill out the application form below for an opportunity to receive one.  Recipients will be determined via a random drawing by R&D Systems, Inc.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key downstream consequences for single (e.g., genetic testing consent) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage scientific disciplines that have not traditionally conducted cancer research such as affective and cognitive neuroscience, decision science, and consumer science to elucidate perplexing and understudied problems in basic affective and decision sciences with promise of having downstream implications for cancer prevention and control science.

To develop new strategies to prevent breast cancer, we need to understand the causes of breast cancer in people, changes in breast cells that give rise to cancer, markers for disease, and how breast cancer progresses. The 2014 Avon Foundation Research Program seeks proposals in these areas to advance understanding of causes of breast cancer and prevention.

The purpose of the Kirschstein-NRSA predoctoral fellowship (F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the applicants dissertation research project and is expected to clearly enhance the individuals potential to develop into a productive, independent research scientist.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services.  Consistent with the goals of this funding initiative and as required by the SF424 instructions for all Phase II SBIR applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.